Nevertheless, the long-term use of PPARδ ligands inpatients susceptible to angiogenic diseases, such as diabetics who are prone toretinopathy or individuals predisposed to cancer, may require particular careand a better understanding of its possible collateral effects. Here, PPARD is linked to diabetes mellitus.